







WOW! BADGER CHALLENGE 2022 WAS AN INCREDIBLY INSPIRING DAY OF JOY, HEART, AND DETERMINATION.

We've always said, community is the cure. And thanks to you and your support we are one step closer.

We have much to celebrate this year. 2022 was a record-breaking year with 2,751 participants who came together in the fight against cancer, with an astounding \$802,761 raised, which brings our cumulative dollars raised to \$2.6 million. Thanks to our sponsors, 100% of participant raised funds have gone directly to research, helping scientists drive science forward to prevent, treat, and cure cancer.

We are excited about the growth of this event and the support of our mission. Your drive and dedication to help us turn more patients into survivors is remarkable. We look forward to seeing where 2023 takes us.

Sincerely.

Dr. Paul Harari & Dr. Deric Wheeler

P. Panai Club



\$802,761

\$2.6 MILLION RAISED SINCE 2016

2022 BADGER CHALLENGE COMMUNITY





28 STATES REPRESENTED

3 COUNTRIES
REPRESENTED







WALKERS

RUNNERS

654

535

2.751 TOTAL PARTICIPANTS

400+ Survivors <u>And Current</u> Patients





62 PARTICIPANTS RAISED \$1,000 OR MORE



350 Volunteers

155 TEAMS



TOP FUNDRAISERS

INDIVIDUAL FUNDRAISERS

| Name | Route |
|------------------------|---------------|
| Melissa Carr | 5K Walk |
| Tim Peerenboom | Half Marathon |
| Katie Kirner | 5K Walk |
| Paul Nelson | 50K Bike |
| Joanie Conley | 25K Bike |
| Andrew Drane | 100K Bike |
| John Neis | Global Biker |
| Kamakshi Sachidanandam | 25K Bike |
| Traci Parker | 100 Mile Bike |
| Hayley Bazarek | 5K Run |

TEAM FUNDRAISERS

| Name | Amount Raised |
|----------------------------|---------------|
| Team Wildflowers | \$15,285 |
| Grandma's Gang | \$10,325 |
| Team Batterman | \$9,686 |
| All Aboard the Grady Train | \$8,540 |
| Aldevron | \$8,387 |
| Blackhawk Country Club | \$8,110 |
| DHO Physics Team | \$6,216 |
| Joanie's Cycopaths | \$6,178 |
| Judi's Humingbirds | \$4,401 |
| APC Team | \$4,250 |

TOP CORPORATE TEAMS

| Name | Team Members |
|-------------------------------------|--------------|
| Arrowhead Pharmaceuticals | 71 |
| Dental Health Associates Madison | 62 |
| American Packaging Corporation | 37 |
| ETC | 37 |
| Batterman | 35 |
| Aldevron | 29 |
| American Family Insurance | 28 |
| Catalent | 22 |
| Invenra | 16 |
| Ayres Associates | 12 |





WHERE THE MONEY GOES - TYPES OF CANCER



BRAIN CANCER



KIDNEY CANCER



OVARIAN CANCER



BREAST CANCER



LEUKEMIA



PANCREATIC CANCER



BLADDER CANCER



LIVER CANCER



PEDIATRIC CANCER



CERVICAL CANCER



LUNG CANCER



PROSTATE CANCER



COLORECTAL CANCER



LYMPHOMA



THYROID CANCER



HEAD & NECK CANCER



MELANOMA



SKIN CANCER

WHERE THE MONEY GOES - DISCIPLINES OF CANCER



















Badger Challenge has given significant contributions to the next evolution of cancer treatment: proton therapy, the most accurate and innovative form of radiation therapy available. The Proton Therapy Center will be housed at the new UW Eastpark Medical Center opening in 2024. We are excited that the Badger Challenge is at the center of innovative technologies.














2022 BADGER CHALLENGE SCHOLARS



DR. AMY FOWLER
Department of Radiology
Breast Cancer

Dr. Fowler's research examines how non-invasive imaging of tumor glucose metabolism can identify breast cancers that would benefit from commonly used endocrine therapies with faster results compared to standard clinical imaging tests.




DR. QUANYIN HU

Department of Phamaceutical Sciences

Pancreatic Cancer

The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor, with less than 6% of patients surviving beyond 5 years. Dr. Hu's research aims to develop a novel treatment strategy to increase the therapeutic efficacy and improve the prognosis of PDAC patients through systematically modulating the immunosuppressive tumor microenvironment and intratumoral microbiota to increase the immune response to immune checkpoint inhibitors.



DR. JING XHANGDepartment of Oncology **Myeloma**

Dr. Xhang's lab developed an animal model highly representative of human high-risk multiple myeloma (hrMM) subset with de novo resistance to the current myeloma frontline treatment. Her research will identify and validate potential therapeutic targets, focusing on epigenetic regulators, for treating hrMM.




DR. IRENE ONGDepartment of Obstetrics and Gynecology

Tumors arise due to genetic alterations, which can lead to the presentation of mutated peptides by human leucocyte antigen (HLA) molecules to elicit T-cells to destroy tumors. Dr. Ong will identify each patient's personalized tumor mutations to design and rank peptides that can bind to and be presented by HLA molecules to T-cells to enable personalized treatments.



DR. JORDAN SLAGOWSKI
Department of Human Oncology
Solid Tumors

Preclinical irradiators are an essential tool for scientists investigating cancer biology and novel treatment approaches but technologically lag the methods used in modern clinical practice. Dr. Slagowski's research is developing a new system to deliver highly conformal radiation treatments in a preclinical setting to improve the translation of research results to outcomes in human cancer patients.



DR. AARON HOSKINS
Department of Biochemistry
Leukemia/Lymphoma

Melanoma

Life-threatening fungal infections are common among immunocompromised cancer patients during chemotherapy or following bone marrow transplantation. Dr. Hoskin's research will focus on new treatments for these infections based on inhibiting essential steps in fungal gene expression.



DR. OLUFUNMILOLA ABRAHAM

Department of Social & Administrative Sciences

Cancer Prevention

Dr. Abraham's team has created a game, OutSMART Cancer, to improve adolescents' and their families' cancer knowledge, increase awareness of cancer prevention, and reduce risky behaviors. Through health literacy principles, content and game design their research will ensure OutSMART Cancer is a culturally appropriate cancer prevention intervention.



DR. GRACE BLITZER
Department of Human Oncology
Endometrial Cancer

Dr. Blitzer and team are conducting a pilot clinical trial investigating a blood test to identify cancer in the blood of women with uterine cancer. This test looks at the cancer DNA in blood and could be used to personalize treatments for uterine cancer patients in the future.

THANKS TO OUR 2022 SPONSORS

PRESENTING SPONSORS













VALUED SPONSORS



























































POWERING RESEARCH. CURING CANCER.